Dr. Smith will strengthen XenoSTART’s position as a premier drug development partner, translating PDX-driven insights into faster, more confident oncology development decisions. The START Center for Cancer Research (“START”), today announced the appointment of Frank Smith, PhD, MBA, as President of XenoSTART, its preclinical business unit. In this role, Dr. Smith will oversee XenoSTART’s operations, […]
Dr. Hafez will lead the new early-phase research site at Los Angeles Cancer Network, one of the nation’s largest and most diverse community-based oncology practices The START Center for Cancer Research (“START”), the world’s largest community-based network specializing in early-phase oncology trials, today announced the appointment of Navid Hafez, MD, MPH, as Director of Clinical
The first START site in New York launches new strategic partnership to provide cutting-edge cancer research Northwell Health and The START Center for Cancer Research held a ceremonial ribbon-cutting to unveil Northwell-START New York-Long Island, which reflects a $5.7 million investment for a 10,000-square foot, state-of-the-art early-phase cancer clinical trial center. Located at Northwell’s outpatient
New START site at HM Montepríncipe University Hospital offers clinical trial access for children with cancer The START Center for Cancer Research (“START”), the world’s largest community-based network specializing in early-phase oncology clinical trials, together with HM Hospitales, announces the launch of a pediatric onco-hematology clinical research unit at HM Montepríncipe University Hospital in Madrid.
Expanded partnership positions XenoSTART and Minerva Imaging at the forefront of radiopharmaceuticals — one of the fastest-growing areas in oncology drug development. The START Center for Cancer Research (“START”), its preclinical division XenoSTART, and Minerva Imaging today announced an expansion of their decade-long partnership to establish the industry’s most comprehensive integrated platform for radiopharmaceutical drug
START enhances its global leadership by integrating Advarra’s advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve pressure on the oncology drug development ecosystem The START Center for Cancer Research (“START”), the leading global community-based early-phase oncology research network, today announced a strategic partnership with Advarra, the premier
The START Center for Cancer Research (“START”), the world’s largest early-phase community-based cancer trial site network, today announced the launch of the START Hope Hub, a powerful new digital patient and physician-focused platform that connects patients, caregivers, advocacy groups, and referring oncologists with quick access to START’s 720+ oncology clinical trials and informational resources. With
Partnership Will Launch Three New START Research Sites to Bring Early Phase Trials Closer to Patients in Major U.S. Communities The START Center for Cancer Research (“START”), and OneOncology today announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN, California), The Center for Cancer
START and OneOncology Partner To Expand Access to Early Phase Oncology Trials Read More »
Major study milestone highlights START’s commitment to bringing novel cancer therapies to patients through community-based early-phase clinical trials The START Center for Cancer Research (“START”), the world’s largest early-phase community-based oncology site network, today announced the dosing of the first U.S. participant in Moderna’s Phase 1 study evaluating mRNA-4106, a novel Pan-Tumor Antigen Therapy candidate, in
START’s Site Network Solidifies its Global Leadership in Urological Cancer Trials The START Center for Cancer Research (“START”), a global leader in early-phase oncology clinical trials, announces the expansion of its network with the acquisition of Carolina Urologic Research Center (“CURC”) the premier urologic clinical research site specializing in genitourinary (GU) oncology. This acquisition strengthens
Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.
